Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE In addition, the use of anti-angiogenic agents significantly improved overall survival (OS) in mCRC patients with KRAS wide type (HR 0.78, 95%CI: 0.70-0.86, p<0.001) or KRAS mutant status (HR 0.87, 95%CI: 0.77-0.98, p=0.018). 31838964

2020

Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE KRAS and BRAF mutations are prognostic and predictive tools in metastatic colorectal cancer, but little is known about their prognostic value in patients scheduled for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). 31571052

2020

Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE To compare anti-EGFR and anti-VEGF agents in patients with K-RAS wild-type metastatic colorectal cancer (mCRC) with regards to tumor location. 31646798

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Panitumumab, an anti-epithelial growth factor receptor (EGFR) antibody, has been known to be effective treatments for wild-type KRAS metastatic colorectal cancer (mCRC). 31646791

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Addition of anti-EGFR in left sided K-RAS wild-type mCRC regarding PFS was beneficial, however there was no difference in terms of OS. 31646798

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs? 31786833

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE This phase I study of U3-1565, anti-HB-EGF antibody, and Cetu combination therapy enrolled patients with KRAS wild-type metastatic colorectal cancer who had received two ≤ regimens with fluoropyrimidine, oxaliplatin, irinotecan, and Cetu/Pani and had disease progression on Cetu/Pani. 31020609

2020

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE To assess whether regorafenib and TAS-102 treatments are associated with a change in Skeletal Muscle Area (SMA) as well as to compare Skeletal Muscle Mass (SMM) loss levels between regorafenib and TAS-102 treatments and prognostic significance in the patients with metastatic colorectal cancer (mCRC). 31786894

2020

Entrez Id: 4255
Gene Symbol: MGMT
MGMT
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Promising, albeit limited, activity and efficacy of temozolomide have been reported in pretreated patients with metastatic colorectal cancer bearing MGMT promoter methylation. 31821983

2020

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study. 31820199

2020

Entrez Id: 673
Gene Symbol: BRAF
BRAF
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Tumor sidedness and efficacy of first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer: A network meta-analysis. 31783291

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE KRAS and BRAF mutations are prognostic and predictive tools in metastatic colorectal cancer, but little is known about their prognostic value in patients scheduled for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). 31571052

2020

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors. 31679083

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE The HER2 positivity was 2.9% (43/1490) and 2.6% (39/1490) in CRCs based on the GEA criteria and the HERACLES criteria, and 3.7% (9/243) in mCRC according to both criteria. 31720832

2020

Entrez Id: 7157
Gene Symbol: TP53
TP53
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Co-Altered Ras/B-raf and TP53 is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Metastatic Colorectal Cancer Patients. 31719050

2020

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Direct randomized comparisons of regorafenib, TAS-102, and fruquintinib for treating metastatic colorectal cancer (mCRC) are lacking. 31848739

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Progression-free survival (PFS) rates were not significantly different for KRAS-WT mCRC and all RAS-WT mCRC between the two groups. 29383654

2020

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Prognostic importance of tumor location and anti-EGFR therapy in patients with K-RAS wild type metastatic colorectal cancer. 31646798

2020

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE The development of monoclonal antibodies (mAbs) cetuximab and panitumumab, which target the transmembrane protein epidermal growth factor receptor (EGFR), mark a major step forward in the treatment of metastatic colorectal cancer (mCRC). 30623369

2019

Entrez Id: 2212
Gene Symbol: FCGR2A
FCGR2A
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer. 31097738

2019

Entrez Id: 2212
Gene Symbol: FCGR2A
FCGR2A
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer. 30796344

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer. 30621206

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer. 31097738

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer. 30924091

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE <b>Background:</b> Anti-EGFR mAb are recommended treatment for metastatic colorectal cancer (mCRC). 31220949

2019